There are 2949 resources available
Chair’s welcome and introductions
Presenter: Ana Oaknin
Session: AstraZeneca - Redefining long-term outcomes in the era of personalised medicine: Maintenance treatment in newly diagnosed ovarian cancer
Resources:
Webcast
Pioneering with PARP inhibition: rationale for maintenance therapy in newly diagnosed ovarian cancer
Presenter: Thomas Herzog
Session: AstraZeneca - Redefining long-term outcomes in the era of personalised medicine: Maintenance treatment in newly diagnosed ovarian cancer
Resources:
Webcast
Optimising clinical outcomes: the case for personalised medicine in ovarian cancer
Presenter: Ignace Vergote
Session: AstraZeneca - Redefining long-term outcomes in the era of personalised medicine: Maintenance treatment in newly diagnosed ovarian cancer
Resources:
Webcast
Panel discussion
Presenter: Ignace Vergote
Session: AstraZeneca - Redefining long-term outcomes in the era of personalised medicine: Maintenance treatment in newly diagnosed ovarian cancer
Resources:
Webcast
Summary and meeting close
Presenter: Ana Oaknin
Session: AstraZeneca - Redefining long-term outcomes in the era of personalised medicine: Maintenance treatment in newly diagnosed ovarian cancer
Resources:
Webcast
Exploring the emerging research with immuno-oncology in CSCC
Presenter: Dirk Schadendorf
Session: Sanofi Genzyme - Immune checkpoint blockade in non-melanoma skin cancer
Resources:
Webcast
Broadening horizons: new data and combinations with PARP inhibitors
Presenter: Isabelle Ray-Coquard
Session: AstraZeneca - Redefining long-term outcomes in the era of personalised medicine: Maintenance treatment in newly diagnosed ovarian cancer
Resources:
Webcast
Introduction
Presenter: Giuseppe Curigliano
Session: ESMO Colloquium supported by Eli Lilly and Company: Precision Medicine Implementation in the Clinic: RET as a potential target in cancer treatment
Resources:
Slides
Webcast
Introduction to RET mutations and fusions and their incidence for potential use as target in cancer treatment
Presenter: Alexander Drilon
Session: ESMO Colloquium supported by Eli Lilly and Company: Precision Medicine Implementation in the Clinic: RET as a potential target in cancer treatment
Resources:
Slides
Webcast
RET fusion TKI: Present results and recent developments in Lung cancer
Presenter: David Planchard
Session: ESMO Colloquium supported by Eli Lilly and Company: Precision Medicine Implementation in the Clinic: RET as a potential target in cancer treatment
Resources:
Slides
Webcast